Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
PMID: 30496458

Abstract

BACKGROUND: In the experimental arm of the OFLOTUB trial, gatifloxacin replaced ethambutol in the standard 4-month regimen for drug-susceptible pulmonary tuberculosis. The study included a nested pharmacokinetic (PK) study. We sought to determine if PK variability played a role in patient outcomes.

Authors

  • Jotam G Pasipanodya
    Center for Infectious Diseases Research & Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, TX, USA.
  • Wynand Smythe
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa.
  • Corinne S Merle
    Faculty of Epidemiology and Population Health, Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, United Kingdom.
  • Piero L Olliaro
    Special Programme on Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland.
  • Devyani Deshpande
    Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas.
  • Gesham Magombedze
    Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas.
  • Helen McIlleron
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa.
  • Tawanda Gumbo
    The Cardiac Clinic, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa; Center for Infectious Diseases Research & Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, TX, USA.

Keywords

External Resources

Popular Topics
Recent Journals